Some examples of potentially useful biomarker inclusion in early oncology trials
What to watch out for at the ASCO GI19 conference in San Francisco
A look at where we are in pancreatic cancer and how the landscape has evolved of late...
A look at 8 key abstracts being presented at #GI18 in San Francisco this week.
A look at gems from the #GI17 poster halls or molecules destined for Dog Drug Heaven?
A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.
A couple of trials at ASCO #GI17 look promising in terms of trial design with encouraging implications for the future in metastatic colorectal cancer.
Will gastric cancer be one of the next indications for nivolumab?
Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?
Will checkpoint blockade be effective in multiple GI cancers and if so, why?
Which new combinations could improve outcomes for colon cancer patients receiving EGFR therapies by overcoming acquired resistance?
We've seen very little real progress in colorectal cancer beyond incremental improvements since Erbitux and Avastin were approved a decade ago. Are we on the threshold of a new paradigm shift?
Patients with BRAF driven colon cancer don't do as well as those with melanoma: how can we overcome acquired resistance to RAF treatment?
If we truly want to see a more precision medicine approach evolve then we have to first find the oncogenic drivers. At ASCO GI one study in particular caught my eye and attention, but you won’t find it written up in the medical lay press and it’s not that obvious unless you know what you’re looking for.
“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.
Preview of some of the key data being presented at ASCO GI in San Francisco this month.